BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs2230926
,
DRD2
,
Fatty acid metabolic process
,
Diabetes mellitus
,
Intestine
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
PD-L2
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Superior cervical ganglion
Heart ventricle
Heart
Kidney
Atrioventricular node
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Stachybotryotoxicosis
Disease caused by parasite
Toxic effect of mycotoxin
Toxoplasmosis
Mycobacteriosis
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Menthol
trinitrophenyl-bovine serum albumin
icilin
linalool
Leishmaniasis Vaccines
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
PWWP2A
ITCH
RIPK1
FEN1
MIR142
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Exome sequencing identifies PD-L2 as a potential predisposition gene for lymphoma.
PD-L1 and PD-L2 Mutations in Pediatric Hodgkin Lymphoma: Do They Have Any Prognostic Significance?
Programmed death-ligand 2 (PD-L2) expression in bladder cancer.
PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune inf…
Differential expression of PD‑L1 and PD‑L2 is associated with the tumor microenvironment of TILs and…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma
Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.
A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumo…
Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcino…
Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Met…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ